Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    DFR Gold

    MCap

    CAD10m

    Last close

    CAD0.06

    ▲ 0.05 (81.82%)

    Biodexa Pharmaceuticals

    MCap

    USD3m

    Last close

    USD5.11

    ▲ 1.61 (46.00%)

    Quadrise

    MCap

    GBP22m

    Last close

    GBP0.03

    ▲ 0.77 (43.02%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

Kazia Therapeutics (NASDAQ: KZIA)

Currency in

Last close As at 04/12/2023

1.32

▲ 0.04 (3.13%)

Market capitalisation

22m

Kazia Therapeutics’ lead asset paxalisib (a PI3K inhibitor that can cross the blood brain barrier (BBB), licensed from Genentech) is in a pivotal study for glioblastoma (GBM) and in early-stage studies in childhood brain cancers, DIPG and AT/RT. Phase I EVT801 is an inhibitor of VEGFR3.

Latest Insights

View More

Healthcare | Flash note

Kazia Therapeutics — Reinvestment period with increased R&D focus

Healthcare | ADR Flash

Kazia Therapeutics — Collaboration may expand utility to combo therapies

Healthcare | Update

Kazia Therapeutics — EVT801 data published in peer-reviewed journal

Healthcare | Flash note

Kazia Therapeutics — Q123 cash flows in line with our estimates
Visit Website

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Nidhi Singh

Analyst

Adam McCarter

Adam McCarter

Associate Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Arron Aatkar

Associate analyst

Key Management

  • Iain Ross

    Chairman

  • John Friend

    CEO

  • Karen Krumeich

    CFO

Balance Sheet

Forecast net debt (US$m)

6

Forecast gearing ratio (%)

224

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 7.1 28.2 (77.5)
Relative 3.2 19.1 (78.4)
52 week high/low US$6.0/US$0.5

Financials

Edison Investment Research is terminating coverage on Kazia Therapeutics (KZA). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Y/E Jun Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (fd) (c) P/E (x) P/CF (x)
2021A 10.7 (3.1) (3.1) (25.09) N/A N/A
2022A 0.0 (14.9) (14.9) (110.57) N/A N/A
2023E 0.0 (19.0) (19.0) (111.41) N/A N/A
2024E 10.8 (17.2) (17.2) (82.84) N/A N/A

Research

ADR Flash

Healthcare

Kazia Therapeutics — Collaboration may expand utility to combo therapies

Update

Healthcare

Kazia Therapeutics — EVT801 data published in peer-reviewed journal

Healthcare

Flash note

Kazia Therapeutics — Reinvestment period with increased R&D focus
View All

Thematics

View All

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free